found that the baseline levels of anti-thyroglobulin and anti-thyroid peroxidase antibodies were higher in NSCLC patients who developed thyroiditis after the PD-1 inhibitor treatment (109). This evidence concerns the gene TPO and non-small cell lung carcinoma.